Evofem appoints Ivy Zhang as CFO and Secretary; interim CFO Albert Altro departs

Evofem Biosciences, Inc.

Albert Altro's interim CFO appointment terminated immediately April 13; Traverse engagement to end by April 30.
Saundra Pelletier resigned as Secretary but remains CEO; Ivy Zhang appointed CFO and Secretary effective April 13.
Ivy Zhang receives annual base salary of $410,000, eligible for bonus up to 40% of salary, and standard benefits.
Zhang previously served as Evofem's Controller (2020-2022) and Director of SEC Reporting; returns from HUYABIO.
CEO Saundra Pelletier stated goal to achieve quarterly EBITDA breakeven by end of 2023 with Zhang's leadership.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Ivy Zhang

Chief Financial Officer and Secretary

EVFM · Evofem Biosciences, Inc.

Effective: 2023-04-13
Filed: April 14, 2023, 7:59 PM ET

Ivy Zhang was appointed as the Chief Financial Officer and Secretary of the Company, effective immediately.

Departed (interim)

Albert Altro

interim Chief Financial Officer

EVFM · Evofem Biosciences, Inc.

Effective: 2023-04-13
Successor: Ivy Zhang
Filed: April 14, 2023, 7:59 PM ET

Albert Altro’s appointment as the Company’s interim Chief Financial Officer terminated, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Ivy Zhang was appointed as Chief Financial Officer and Secretary at Evofem Biosciences, Inc..

Action: appointed
Role: Chief Financial Officer and Secretary

Exact text from the filing

Ivy Zhang was appointed as the Chief Financial Officer and Secretary of the Company, effective immediately.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Albert Altro was terminated as interim Chief Financial Officer at Evofem Biosciences, Inc..

Action: terminated
Role: interim Chief Financial Officer

Exact text from the filing

Albert Altro’s appointment as the Company’s interim Chief Financial Officer terminated, effective immediately.

View on SEC.gov

Evofem Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-012220

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.